In this paper, we discuss a response adaptive randomization method, and why it should be used in clinical trials for rare diseases compared to a randomized controlled trial with equal fixed randomizat
Primary objectives: The principle end-point of the study is to evaluate the therapeutic response achieved in patients with metastatic colorectal cancer with high espression of the enzyme thymidilate s